Comparison of long-term efficacy, tolerability and drug survival rates of baricitinib as monotherapy or combination therapy in RA patients: data from a real-world prospective cohort study
In this real-world cohort, baricitinib demonstrated sustained long-term effectiveness, drug survival and an acceptable safety profile. The similar outcomes observed for MONO and COMBO indicate that baricitinib may be used effectively as MONO in patients with RA for whom MTX is not suitable or tolerated.
Authors
- Selahattin Alp Temiz (ORCID: https://orcid.org/0000-0003-0804-3198)
- Axel J. Hueber (ORCID: https://orcid.org/0000-0001-6454-1234)
- Georg Schett
- Arnd Kleyer (ORCID: https://orcid.org/0000-0002-2026-7728)
- Koray Taşçılar (ORCID: https://orcid.org/0000-0002-8109-826X)
- F Hartmann (ORCID: https://orcid.org/0000-0001-6106-1657)
- Sara Bayat (ORCID: https://orcid.org/0000-0002-2799-184X)
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Nuremberg Hospital (DE)
- Paracelsus Medizinische Privatuniversität (DE)
- Charité - Universitätsmedizin Berlin (DE)
Publication Details
- Journal
- RMD Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/rmdopen-2025-006333
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Deutsche Forschungsgemeinschaft
- Leibniz-Gemeinschaft